The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Phase II Results for Cabozantinib in RET-Rearranged Lung Cancer

Christine M. Lovly, MD, PhD
Published Online:3:59 PM, Mon August 14, 2017

Christine M. Lovly, MD, PhD, assistant professor of medicine (hematology/oncology), assistant professor of cancer biology, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses phase II results for cabozantinib (Cabometyx) in patients with RET-rearranged lung cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.